SCHEMBL22050847

SCHEMBL22050847

COC(=O)c1cc(S(=O)(=O)N2CCCC2)cn1CC(=O)c1ccc(-c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.46
▸ LMNA P02545 4/20 0.44
▸ TDP1 Q9NUW8 2/20 0.44
▸ POLB P06746 2/20 0.44
▸ THRB P10828 1/20 0.44
▸ MAPT P10636 4/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ GAA P10253 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ NPSR1 Q6W5P4 3/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ GLA P06280 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22050501 0.91 TP53 (0.49) TP53LMNATDP1POLBTHRB
SCHEMBL22051968 0.90 TP53 (0.47) TP53LMNATDP1POLBTHRB
SCHEMBL22051362 0.88 TP53 (0.46) TP53LMNATDP1POLBTHRB
SCHEMBL22050850 0.85 TP53 (0.44) TP53LMNATDP1POLBTHRB
SCHEMBL24212087 0.84 GRIN2B (0.43) TP53LMNATDP1POLBTHRB
SCHEMBL18038967 0.83 GAA (0.47) TP53LMNAPOLBMAPTALDH1A1
SCHEMBL30207105 0.83 GAA (0.47) TP53LMNAPOLBMAPTALDH1A1
SCHEMBL22050836 0.83 KMT2A (0.42) TP53LMNAPOLBMAPTALDH1A1
SCHEMBL18038998 0.82 GAA (0.46) TP53LMNAPOLBMAPTALDH1A1
SCHEMBL22051947 0.81 PLAU (0.40) POLBMAPTALDH1A1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017486-A1 DOCK1-INHIBITING COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-01-20 — — US claimed
EP-3888651-A1 DOCK1-INHIBITING COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2021-10-06 — — EP claimed
US-20220017486-A1 DOCK1-INHIBITING COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-01-20 — — US disclosed
US-20220017486-A1 DOCK1-INHIBITING COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-01-20 — — US disclosed
EP-3888651-A1 DOCK1-INHIBITING COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2021-10-06 — — EP disclosed
EP-3888651-A1 DOCK1-INHIBITING COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2021-10-06 — — EP disclosed
WO-2020111252-A1 DOCK1-INHIBITING COMPOUND AND USE THEREOF 国立大学法人九州大学 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017486-A1 DOCK1-INHIBITING COMPOUND AND USE THEREOF DOCK2, DOCK11, DOCK5 TP53 1002/4885LMNA 3641/4885TDP1 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback